Prognostic significance of tumor oxygenation in humans

Cancer Letters

Volumn 195, Issue 1, 2003, Pages 1-16

  Evans, Sydney M ^a   Koch, Cameron J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

2 Nitroimidazole; CA9; EF5; HIF1; Hypoxia; PET imaging; Polarographic needle electrodes; Prognosis; Radiation resistance; SPECT imaging

Indexed keywords

2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; COPPER 64; COPPER 67; FLUORINE 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINE 123; IODOAZOMYCIN ARABINOSIDE I 123; ISOENZYME; OSTEOPONTIN; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; OXYGEN; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; THROMBOSPONDIN; UNCLASSIFIED DRUG; UPENAZIME; VASCULOTROPIN;

ANALYTIC METHOD; CLINICAL TRIAL; DEVICE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; OXYGEN ELECTRODE; OXYGEN TISSUE LEVEL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE SARCOMA; TISSUE OXYGENATION; UTERINE CERVIX CANCER;

EID: 0038293080     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(03)00012-0     Document Type: Review

References (145)

1. J.D. Chapman, A.J. Franko, C.J. Koch, The fraction of hypoxic clonogenic cells in tumor populations, in Biological Bases and Clinical Implications of Tumor Radioresistance, 1983, pp. 61-73.
2. Moulder J.E., Martin D.F. Hypoxic fraction determinations in the BA1112 rat sarcoma: variations within and among assay techniques. Radiat. Res. 1984;99.
3. Kennedy K.A., Teicher B.A., Rockwell S., Sartorelli A.C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol. 29:1980;1-8.
4. Henk J.M. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers. Int. J. Radiat. Oncol. Biol. Phys. 12:1986;1339-1341.
5. Henk J.M., Smith C.W. Radiotherapy and hyperbaric oxygen in head and neck cancer: interim report of the second clinical trial. Lancet. 2:1977;104-105.
6. Overgaard J., Hansen H., Sandersen A.P., Hjelm-Hansen M., Jorgensen K., Sandberg E., et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx: report from the DAHANCA 2 study. Int. J. Radiat. Oncol. Biol. Phys. 16:1989;1065-1068.
7. Overgaard J. Importance of tumor hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother. Oncol. 24:1992;S64.
8. Phillips T.L., Wasserman T.H., Johnson R.J., Levin V.A., VanRaalte G. Final report on the United States phase I clinical trial of the hypoxic cell radiosensitizer, misonidazole (RO-07-0582; NSC #261037). Cancer. 48:1981;1687-1704.
9. Urtasun R.C., Coleman C.N., Wasserman T.H., Phillips T.L. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int. J. Radiat. Oncol., Biol., Phys. 10:1984;1691-1696.
10. Lesniak M.S., Langer R., Brem H. Drug delivery to tumors of the central nervous system. Curr. Neurol. Neurosci. Rep. 1:2001;210-216.
11. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9:1990;253-266.
12. Brown D.M., Gonsalez-Mendez R., Brown J.M. Factors influencing intracellular uptake and radiosensitization by 2-nitroimidazoles in vitro. Radiat. Res. 93:1983;492-505.
13. Horan A.D., Koch C.J. The K(m) for radiosensitization of human tumor cells by oxygen is much greater than 3 mmHg and is further increased by elevated levels of cysteine. Radiat. Res. 156:2001;388-398.
14. Koch C.J., Evans S.M. Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. Int. J. Cancer. 67:1996;661-667.
15. Koch C.J., Skov K.A. Enhanced radiation-sensitivity by preincubation with nitroimidazoles: effect of glutathione depletion. Int. J. Radiat. Oncol., Biol., Phys. 29:1994;345-349.
16. Ling C., Michaels H., Epp E., Peterson E. Interaction of misonidazole and oxygen in the radiosensitization of mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 6:1980;583-589.
17. Olive P. Range of oxygenation in SiHa tumor xenografts. Radiat. Res. 158:2002;159-166.
18. Wouters B.G., Brown J.M. Cells at intermediate oxygen levels can be more important than the 'hypoxic fraction' in determining tumor response to fractionated radiation therapy. Radiat. Res. 147:1997;541-550.
19. Woods M.L., Koch C.J., Lord E.M. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole. EF5, and monoclonal antibodies. Int. J. Radiat. Oncol., Biol., Phys. 34:1996;93-101.
20. Laughlin K.M., Evans S.M., Jenkins W.T., Tracy M., Chan C.Y., Lord E.M., et al. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J. Pharmacol. Exp. Therap. 277:1996;1049-1057.
21. Evans S.M., Jenkins W.T., Joiner B., Lord E.M., Koch C.J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res. 56:1996;405-411.
22. Koch C.J., Oprysko P.R., Shuman A.L., Jenkins W.T., Brandt G., Evans S.M. Radiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsion. Cancer Res. 62:2002;3626-3629.
23. Evans S., Hahn S., Magarelli D., Koch C. Hypoxic heterogeneity in human tumors: EF5 binding, vasculature, necrosis and proliferation. Am. J. Clin. Oncol. 24:2001;467-472.
24. C. Koch, Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and the 2-nitroimidazole EF5, in Antioxidants and Redox Signaling, Packer, Editor. 2001, Academic Press: San Diego, California.
25. Grzybicki D.M., Moore S.A. Implications of prognostic markers in brain tumors. Clin. Lab. Med. 19:1999;833-847.
26. Stone H.B., Brown J.M., Phillips T.L., Sutherland R.M. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat. Res. 136:1993;422-434.
27. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6:1994;509-518.
28. Kaanders J.H., Pop L.A., Marres H.A., Bruaset I., van den Hoogen F.J., Merkx M.A., et al. Experience in 215 patients with advanced head-and-neck cancer. Int. J. Radiat. Oncol., Biol., Phys. 52:2002;769-778.
29. Dorie M.J., Kovacs M.S., Gabalski E.C., Adam M., Le Q.T., Bloch D.A., et al. Damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. Neoplasia (New York). 1:1999;461-467.
30. Del Rowe J., Scott C., Werner-Wasik M., Bahary J.P., Curran W.J., Urtasun R.C., et al. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 18:2000;1254-1259.
31. Lord E.M., Harwell L., Koch C.J. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 53:1993;5271-5276.
32. 2 saturation measurements. Br. J. Cancer. 79:1999;464-471.
33. Taylor N.J., Baddeley H., Goodchild K.A., Powell M.E., Thoumine M., Culver L.A., et al. BOLD MRI human tumor oxygenation during carbogen breathing. J. Magnet. Reson. Imaging. 14:2001;156-163.
34. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:2000;7075-7083.
35. Ziemer L., Koch C., Maity A., Magarelli D., Horan A., Evans S. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia. 6:2001;500-508.
36. Kaluz S., Kaluzová M., Chrastina A., Olive P.L., Pastoreková S., Pastorek J., et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 stabilization. Cancer Res. 62:2002;4469-4477.
37. Walenta S., Salameh A., Lyng H., Evensen J.F., Mitze M., Rofstad E.K., et al. Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am. J. Pathol. 150:1997;409-415.
38. Nelson J.S., Tsukada Y., Schoenfeld D., Fulling K., Lamarche J., Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocyticgliomas. Cancer. 52:1983;550-554.
39. Costa J., Wesley R.A., Glatstein E., Rosenberg S.A. The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer. 53:1984;530-541.
40. Kolstad P. Oslo: Oslo. Oslo: Oslo. 1964;Universitetsforlaget, Oslo, Norway.
41. Gatenby R.A., Coia L.R., Richter M.P., Katz H., Moldofsky P.J., Engstrom P., et al. Oxygen tension in human tumors: in vivo mapping using CT-guided probes. Radiology. 156:1985;211-214.
42. Wendling P., Manz R., Thews G., Vaupel P. Heterogeneous oxygenation of rectal carcinomas in humans. A critical parameter for pre-operative irradiation. Adv. Exp. Med. Biol. 180:1984;293-300.
43. Nozue M., Lee I., Yuan F., Teicher B.A., Brizel D.M., Dewhirst M.W., et al. Interlaboratory variation in oxygen tension measurement by Eppendorf 'Histograph' and comparison with hypoxic marker. J. Surg. Oncol. 66:1997;30-38.
44. Jenkins W.T., Evans S.M., Koch C.J. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int. J. Radiat. Oncol., Biol., Phys. 46:2000;1005-1017.
45. 2 tension measurements. Cancer Res. 51:1991;6098-6102.
46. Brizel D.M., Rosner G.L., Harrelson J., Prosnitz L.R., Dewhirst M.W. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int. J. Radiat. Oncol., Biol., Phys. 30:1994;635-642.
47. Adam M.F., Gabalski E.C., Bloch D.A., Oehlert J.W., Brown J.M., Elsaid A.A., et al. Tissue oxygen distribution in head and neck cancer patients. Head Neck. 21:1999;146-153.
48. Movsas B., Chapman J.D., Horwitz E.M., Pinover W.H., Greenberg R.E., Hanlon A.L., et al. Hypoxic regions exist in human prostate carcinoma. Urology. 53:1999;11-18.
49. Rampling R., Cruickshank G., Lewis A.D., Fitzsimmons S.A., Workman P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol., Biol., Phys. 29:1994;427-431.
50. Koong A.C., Mehta V.K., Le Q.T., Fisher G.A., Terris D.J., Brown J.M., Bastidas A.J., Vierra M. Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol., Biol., Phys. 48:2000;919-922.
51. Lartigau E., Randrianarivelo H., Avril M.F., Margulis A., Spatz A., Eschwege F., et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res. 7:1997;400-406.
52. Hockel M., Knoop C., Schlenger K., Vorndran B., Baussmann E., Mitze M., et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:1993;45-50.
53. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515.
54. Nordsmark M., Hoyer M., Keller J., Nielsen O.S., Jensen O.M., Overgaard J. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int. J. Radiat. Oncol., Biol., Phys. 35:1996;701-708.
55. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56:1996;941-943.
56. 2 availability in vitro and in vivo. Ann. Anat. 183:2001;243-249.
57. Maxwell P.H., Pugh C.W., Ratcliffe P.J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 11:2001;293-299.
58. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours [see comments]. Hypoxia-mediated selection of cells with diminished. Nature. 379:1996;88-91.
59. Young S.D., Marshall R.S., Hill R.P. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. USA. 85:1988;9533-9537.
60. A. Fyles, Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. [see comments.], (2002).
61. Chapman J.D. Hypoxic sensitizers - implications for radiation therapy. New Engl. J. Med. 301:1979;1429-1432.
62. Varghese A.J., Gulyas S., Mohindra J.K. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 36:1976;3761-3765.
63. Raleigh J.A., Koch C.J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40:1990;2457-2464.
64. Koch C.J., thin-film A. culturing technique allowing rapid gas-liquid equilibration (6 sec) with no toxicity to mammalian cells. Radiat. Res. 97:1984;434-442.
65. Taylor Y.C., Rauth A.M. Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 38:1978;2745-2752.
66. 14C]misonidazole in multicell spheroids. Radiat. Res. 101:1985;473-479.
67. 14C-misonidazole. Br. J. Radiol. 56:1983;745-753.
68. 14C-misonidazole to hypoxic cells in V79 spheroids. Br. J. Cancer. 45:1982;694-699.
69. Parliament M.B., Wiebe L.I., Franko A.J. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br. J. Cancer. 66:1992;1103-1108.
70. Chapman J.D., Gillespie C.J. Radiation-induced events and their time scale in mammalian cells. Adv. Radiat. Biol. 9:1981;143-198.
71. Raleigh J.A., Chou S.C., Calkins-Adams D.P., Ballenger C.A., Novotny D.B., Varia M.A. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. Clin. Cancer Res. 6:2000;855-862.
72. Wijffels K.I., Kaanders J.H., Rijken P.F., Bussink J., van den Hoogen F.J., Marres H.A., et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br. J. Cancer. 83:2000;674-683.
73. Koch C.J., Hahn S.M., Rockwell K. Jr., Covey J.M., McKenna W.G., Evans S.M. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother. Pharmacol. 48:2001;177-187.
74. Evans S.M., Hahn S., Pook D.R., Jenkins W.T., Chalian A.A., Zhang P., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 60:2000;2018-2024.
75. Evans S.M., Hahn S.M., Magarelli D.P., Zhang P.J., Jenkins W.T., Fraker D.L., et al. Hypoxia in human intraperitoneal and extremity sarcomas. Int. J. Radiat. Oncol., Biol., Phys. 49:2001;587-596.
76. Dennis M.F., Stratford M.R., Wardman P., Watts M.E. Cellular uptake of misonidazole and analogues with acidic or basic functions. Int. J. Radiat. Biol. Relat. Stud. Phys., Chem. Med. 47:1985;629-643.
77. Chou S.C., Flood P.M., Raleigh J.A. Marking hypoxic cells for complement and cytotoxic T lymphocyte-mediated lysis: using pimonidazole. Br. J. Cancer Suppl. 27:1996;S213-S216.
78. Raleigh J.A., Miller G.G., Franko A.J., Koch C.J., Fuciarelli A.F., Kelly D.A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. Br. J. Cancer. 56:1987;395-400.
79. Gross M.W., Karbach U., Groebe K., Franko A.J., Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int. J. Cancer. 61:1995;567-573.
80. Biaglow J.E., Manevich Y., Leeper D., Chance B., Dewhirst M.W., Jenkins W.T., et al. MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. Int. J. Radiat. Oncol., Biol., Phys. 42:1998;871-876.
81. Kaanders J., Wijffels K., Marres H., Ljungkvist A., Pop L., Hoogen F., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62:2002;7066-7074.
82. Curran W.J. Jr., Scott C.B., Horton J., Nelson J.S., Weinstein A.S., Fischbach A.J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials [see comments]. J. Natl. Cancer Inst. 85:1993;704-710.
83. Jones D.P. Renal metabolism during normoxia, hypoxia, and ischemic injury. Annu. Rev. Physiol. 48:1986;33-50.
84. Pedersen M.W., Holm S., Lund E.L., Hojgaard L., Kristjansen P.E. Coregulation of glucose uptake and vascular endothelial growth factor (VEGF) in two small-cell lung cancer (SCLC) sublines in vivo and in vitro. Neoplasia (New York). 3:2001;80-87.
85. Tsuzuki Y., Fukumura D., Oosthuyse B., Koike C., Carmeliet P., Jain R.K. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha(hypoxia response element(VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 60:2000;6248-6252.
86. Xia G., Kageyama Y., Hayashi T., Kawakami S., Yoshida M., Kihara K. Regulation of vascular endothelial growth factor transcription by endothelial PAS domain protein 1 (EPAS1) and possible involvement of EPAS1 in the angiogenesis of renal cell carcinoma. Cancer. 91:2001;1429-1436.
87. Tendler D.S., Bao C., Wang T., Huang E.L., Ratovitski E.A., Pardoll D.A., Lowenstein C.J. Intersection of interferon and hypoxia signal transduction pathways in nitric oxide-induced tumor apoptosis. Cancer Res. 61:2001;3682-3688.
88. Genius J., Fandrey J. Nitric oxide affects the production of reactive oxygen species in hepatoma cells: implications for the process of oxygen sensing. Free Radic. Biol. Med. 29:2000;515-521.
89. Sugawara J., Suh D.S., Faessen G.H., Suen L.F., Shibata T., Kaper F., et al. Regulation of insulin-like growth factor-binding protein-1 by nitric oxide under hypoxic conditions. J. Clin. Endocrinol. Metab. 85:2000;2714-2721.
90. Kondo K., Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor gene. Exp. Cell Res. 264:2001;117-125.
91. Wykoff C.C., Beasley N., Watson P.H., Campo L., Chia S.K., English R., et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158:2001;1011-1019.
92. Beasley N.J., Wykoff C.C., Watson P.H., Leek R., Turley H., Gatter K., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. Cancer Res. 61:2001;5262-5267.
93. Chia S.K., Wykoff C.C., Watson P.H., Han C., Leek R.D., Pastorek J., et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 19:2001;3660-3668.
94. Detmar M. Tumor angiogenesis. J. Invest. Dermatol. Symp. Proc. 5:2000;20-23.
95. Laderoute K.R., Alarcon R.M., Brody M.D., Calaoagan J.M., Chen E.Y., Knapp A.M., et al. Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor. Clin. Cancer Res. 6:2000;2941-2950.
96. Sodhi C.P., Phadke S.A., Batlle D., Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes. 50:2001;1482-1490.
97. Zagzag D., Zhong H., Scalzitti J.M., Laughner E., Simons J.W., Semenza G.L. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer. 88:2000;2606-2618.
98. Aebersold D.M., Burri P., Beer K.T., Laissue J., Djonov V., Greiner R.H., et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 61:2001;2911-2916.
99. Waleh N.S., Brody M.D., Knapp M.A., Mendonca H.L., Lord E.M., Koch C.J., et al. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res. 55:1995;6222-6226.
100. Rosmorduc O., Wendum D., Corpechot C., Galy B., Sebbagh N., Raleigh J., et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am. J. Pathol. 155:1999;1065-1073.
101. Raleigh J.A., Calkins-Adams D.P., Rinker L.H., Ballenger C.A., Weissler M.C., Fowler W.C. Jr., et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. Cancer Res. 58:1998;3765-3768.
102. Parliament M.B., Allalunis-Turner M.J., Franko A.J., Olive P.L., Mandyam R., Santos C., et al. Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours. Br. J. Cancer. 82:2000;635-641.
103. Chiarotto J.A., Hill R.P. A quantitative analysis of the reduction in oxygen levels required to induce up-regulation of vascular endothelial growth factor (VEGF) mRNA in cervical cancer cell lines. Br. J. Cancer. 80:1999;1518-1524.
104. Ivanov S.V., Kuzmin I., Wei M.H., Pack S., Geil L., Johnson B.E., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA. 95:1998;12596-12601.
105. Zavada J., Zavadova Z., Pastorekova S., Ciampor F., Pastorek J., Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer. 54:1993;268-274.
106. Loncaster J.A., Harris A.L., Davidson S.E., Logue J.P., Hunter R.D., Wycoff C.C., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61:2001;6394-6399.
107. Olive P.L., Aquino-Parsons C., MacPhail S.H., Liao S.Y., Raleigh J.A., Lerman M.I., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 61:2001;8924-8929.
108. Ballinger J.R. Imaging hypoxia in tumors. Semin. Nuclear Med. 31:2001;321-329.
109. Rischin D., Peters L., Hicks R., Hughes P., Fisher R., Hart R., et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19:2001;535-542.
110. 18F fluoromisonidazole: a pretherapy study of 37 patients. Int. J. Radiat. Oncol., Biol., Phys. 36:1996;417-428.
111. Yeh S.H., Liu R.S., Wu L.C., Yang D.J., Yen S.H., Chang C.W., et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur. J. Nucl. Med. 23:1996;1378-1383.
112. Valk P.E., Mathis C.A., Prados M.D., Gilbert J.C., Budinger T.F. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J. Nuclear Med. 33:1992;2133-2137.
113. Lartigau E., Le Ridant A.M., Lambin P., Weeger P., Martin L., Sigal R., et al. Oxygenation of head and neck tumors. Cancer. 71:1993;2319-2325.
114. Sundfor K., Lyng H., Kongsgard U.L., Trope C., Rofstad E.K. Polarographic measurement of pO2 in cervix carcinoma. Gynecol. Oncol. 64:1997;230-236.
115. Groshar D., McEwan A.J., Parliament M.B., Urtasun R.C., Golberg L.E., Hoskinson M., et al. Imaging tumor hypoxia and tumor perfusion. J. Nuclear Med. 34:1993;885-888.
116. Urtasun R.C., Parliament M.B., McEwan A.J., Mercer J.R., Mannan R.H., Wiebe L.I., et al. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br. J. Cancer Suppl. 27:1996;S209-S212.
117. Cruickshank G.S., Rampling R.P., Cowans W. Direct measurement of the PO2 distribution in human malignant brain tumours. Adv. Exp. Med. Biol. 345:1994;465-470.
118. Collingridge D.R., Piepmeier J.M., Rockwell S., Knisely J.P. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother. Oncol. 53:1999;127-131.
119. Iyer R.V., Haynes P.T., Schneider R.F., Movsas B., Chapman J.D. Marking hypoxia in rat prostate carcinomas with beta-D-and 125I azomycin galactopyranoside. J. Nuclear Med. 42:2001;337-344.
120. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nuclear Med. 38:1997;1155-1160.
121. Lewis J.S., Sharp T.L., Laforest R., Fujibayashi Y., Welch M.J. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J. Nuclear Med. 42:2001;655-661.
122. Dehdashti F., Mintum M., Lewis J., et al. Evaluation of tumor hypoxia with Cu-ATSM and PET (abstr.). J. Nuclear Med. 41:2000;34.
123. 18F] EF5 in rats. Eur. J. Nuclear Med. 2002 (in Press).
124. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer [published erratum appears in Radiother. Oncol. 1999 Mar;50(3):371]. Radiother. Oncol. 48:1998;149-156.
125. Pitson G., Fyles A., Milosevic M., Wylie J., Pintilie M., Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int. J. Radiat. Oncol., Biol., Phys. 51:2001;699-703.
126. Sundfor K., Lyng H., Rofstad E.K. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer. 78:1998;822-827.
127. Sundfor K., Lyng H., Trope C.G., Rofstad E.K. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother. Oncol. 54:2000;101-107.
128. Rofstad E.K., Sundfor K., Lyng H., Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer. 83:2000;354-359.
129. Knocke T.H., Weitmann H.D., Feldmann H.J., Selzer E., Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53:1999;99-104.
130. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:1996;31-39.
131. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol., Biol., Phys. 38:1997;285-289.
132. Brizel D.M., Dodge R.K., Clough R.W., Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 53:1999;113-117.
133. Stadler P., Becker A., Feldmann H.J., Hansgen G., Dunst J., Wurschmidt F., et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int. J. Radiat. Oncol., Biol., Phys. 44:1999;749-754.
134. Rudat V., Vanselow B., Wollensack P., Bettscheider C., Osman-Ahmet S., Eble M.J., et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother. Oncol. 57:2000;31-37.
135. Rudat V., Stadler P., Becker A., Vanselow B., Dietz A., Wannenmacher M., et al. Predictive value of the tumor oxygenation by means of pO2 histography in patients with advanced head and neck cancer. Strahlenther. Onkol. 177:2001;462-468.
136. Terris D.J. Head and neck cancer: the importance of oxygen. Laryngoscope. 110:2000;697-707.
137. Nordsmark M., Alsner J., Keller J., Nielsen O.S., Jensen O.M., Horsman M.R., et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer. 84:2001;1070-1075.
138. Saunders M.I., Anderson P.J., Bennett M.H., Dische S., Minchinton A., Stratford M.R., et al. The clinical testing of Ro 03-8799 - pharmacokinetics, toxicology, tissue and tumor concentrations. Int. J. Radiat. Oncol., Biol., Phys. 10:1984;1759-1763.
139. Roberts J.T., Bleehen N.M., Walton M.I., Workman P., A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br. J. Radiol. 59:1986;107-116.
140. Newman H.F., Bleehen N.M., Ward R., Workman P. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). Int. J. Radiat. Oncol., Biol., Phys. 15:1988;677-684.
141. Olive P.L., Banath J.P., Aquino-Parsons C. Measuring hypoxia in solid tumours - is there a gold standard? Acta Oncol. 40:2001;917-923.
142. Begg A.C., Janssen H., Sprong D., Hofland I., Blommestijn G., Raleigh J.A., et al. Hypoxia and perfusion measurements in human tumors - initial experience with pimonidazole and IUdR. Acta Oncol. 40:2001;924-928.
143. Kennedy A.S., Raleigh J.A., Perez G.M., Calkins D.P., Thrall D.E., Novotny D.B., et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int. J. Radiat. Oncol., Biol., Phys. 37:1997;897-905.
144. Kavanagh M.C., Tsang V., Chow S., Koch C., Hedley D., Minkin S., et al. comparison in individual murine tumors of techniques for measuring oxygen levels. Int. J. Radiat. Oncol., Biol., Phys. 44:1999;1137-1146.
145. Siim B.G., Menke D.R., Dorie M.J., Brown J.M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. Cancer Res. 57:1997;2922-2928.